[
  {
    "ts": null,
    "headline": "Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss",
    "summary": "On Saturday, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) said adolescent patients with severe alopecia areata (AA) treated with once-daily oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36. Findings from the Phase 3 BRAVE-AA-PEDS study were presented at the American Academy of Dermatology. AA is an immune system condition that causes patchy hair loss on the scalp, face, and sometimes other",
    "url": "https://finnhub.io/api/news?id=6628bdc57ba6734dbf39385430898d35ae3e99a254d4d7792a06d06a9f9d53a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741697328,
      "headline": "Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss",
      "id": 133193442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "On Saturday, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) said adolescent patients with severe alopecia areata (AA) treated with once-daily oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36. Findings from the Phase 3 BRAVE-AA-PEDS study were presented at the American Academy of Dermatology. AA is an immune system condition that causes patchy hair loss on the scalp, face, and sometimes other",
      "url": "https://finnhub.io/api/news?id=6628bdc57ba6734dbf39385430898d35ae3e99a254d4d7792a06d06a9f9d53a9"
    }
  }
]